Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected].

Wise ES, Armstrong MS, Watson J, Lockwood DN.

PLoS Negl Trop Dis. 2012;6(6):e1688. doi: 10.1371/journal.pntd.0001688. Epub 2012 Jun 26. Erratum in: PLoS Negl Trop Dis. 2012 Sep;6(9). doi:10.1371/annotation/15ab4f39-31e7-40bc-9b15-6e90a612b49a.

2.

Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers.

Lawn SD, Armstrong M, Chilton D, Whitty CJ.

Trans R Soc Trop Med Hyg. 2006 Mar;100(3):264-9. Epub 2005 Nov 9.

PMID:
16289167
3.

Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.

Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, Miranda-Verastegui C, Santamaria-Castrellon G, Ramirez L, Lazo M, De Doncker S, Boelaert M, Robays J, Dujardin JC, Arevalo J, Chappuis F.

Clin Infect Dis. 2008 Jan 15;46(2):223-31. doi: 10.1086/524042.

PMID:
18171254
4.

Experience with New World cutaneous leishmaniasis in travelers.

Scope A, Trau H, Anders G, Barzilai A, Confino Y, Schwartz E.

J Am Acad Dermatol. 2003 Oct;49(4):672-8.

PMID:
14512915
5.

Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis.

Solomon M, Baum S, Barzilai A, Scope A, Trau H, Schwartz E.

J Am Acad Dermatol. 2007 Apr;56(4):612-6. Epub 2007 Feb 5.

PMID:
17276541
6.

[A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety].

Saldanha AC, Romero GA, Merchan-Hamann E, Magalhães AV, Macedo Vde O.

Rev Soc Bras Med Trop. 1999 Jul-Aug;32(4):383-7. Portuguese.

PMID:
10495667
7.

Out-patient parenteral antimicrobial therapy--a viable option for the management of cutaneous leishmaniasis.

Seaton RA, Morrison J, Man I, Watson J, Nathwani D.

QJM. 1999 Nov;92(11):659-67.

PMID:
10542306
8.

Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis.

Soto J, Valda-Rodriquez L, Toledo J, Vera-Navarro L, Luz M, Monasterios-Torrico H, Vega J, Berman J.

Am J Trop Med Hyg. 2004 Nov;71(5):577-81. Erratum in: Am J Trop Med Hyg. 2005 Mar;72(3):359.

PMID:
15569787
9.

Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers.

Solomon M, Pavlotzky F, Barzilai A, Schwartz E.

J Am Acad Dermatol. 2013 Feb;68(2):284-9. doi: 10.1016/j.jaad.2012.06.014. Epub 2012 Aug 1.

PMID:
22858005
10.

New World cutaneous leishmaniasis in returned travellers: treatment failures using intravenous sodium stibogluconate.

Lawn SD, Yardley V, Vega-Lopez F, Watson J, Lockwood DN.

Trans R Soc Trop Med Hyg. 2003 Jul-Aug;97(4):443-5.

PMID:
15259478
11.

The effects of induced diabetes and cutaneous Leishmania infection on the pharmacokinetics of antimony in hamsters.

Radwan MA, Al Jaser MH, Al Rayes ZR.

Ann Trop Med Parasitol. 2007 Mar;101(2):133-42.

PMID:
17316499
13.

Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.

Bermúdez H, Rojas E, Garcia L, Desjeux P, Dujardin JC, Boelaert M, Chappuis F.

Ann Trop Med Parasitol. 2006 Oct;100(7):591-600.

PMID:
16989685
14.

Efficacy of short-duration (twice weekly) intralesional sodium stibogluconate in treatment of cutaneous Leishmaniasis in India.

Bumb RA, Mehta RD, Ghiya BC, Jakhar R, Prasad N, Soni P, Lezama-Davila C, Satoskar AR.

Br J Dermatol. 2010 Oct;163(4):854-8. doi: 10.1111/j.1365-2133.2010.09865.x.

PMID:
20500797
15.

Treatment of cutaneous leishmaniasis in travelers 2009.

Blum JA, Hatz CF.

J Travel Med. 2009 Mar-Apr;16(2):123-31. doi: 10.1111/j.1708-8305.2008.00286.x. Review. No abstract available.

16.
17.

Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.

Brito NC, Rabello A, Cota GF.

PLoS One. 2017 Sep 19;12(9):e0184777. doi: 10.1371/journal.pone.0184777. eCollection 2017. Review.

18.

Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate.

Tallab TM, Bahamdam KA, Mirdad S, Johargi H, Mourad MM, Ibrahim K, el Sherbini AH, Karkashan E, Khare AK, Jamal A.

Int J Dermatol. 1996 Aug;35(8):594-7.

PMID:
8854166
19.

Two cases of Old World cutaneous leishmaniasis in Australian travelers visiting Morocco.

Stewardson AJ, Leder K, Torresi J, Johnson DF.

J Travel Med. 2010 Jul-Aug;17(4):278-80. doi: 10.1111/j.1708-8305.2010.00417.x.

20.

Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.

Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E, Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M.

PLoS Negl Trop Dis. 2012;6(6):e1674. doi: 10.1371/journal.pntd.0001674. Epub 2012 Jun 19.

Supplemental Content

Support Center